These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 26222558)

  • 1. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
    N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
    Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
    Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural Approaches to Cancer Drug Development.
    Chabner B; Richon V
    N Engl J Med; 2015 Jul; 373(5):402-3. PubMed ID: 26222556
    [No Abstract]   [Full Text] [Related]  

  • 5. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.
    Butowski N; Colman H; De Groot JF; Omuro AM; Nayak L; Wen PY; Cloughesy TF; Marimuthu A; Haidar S; Perry A; Huse J; Phillips J; West BL; Nolop KB; Hsu HH; Ligon KL; Molinaro AM; Prados M
    Neuro Oncol; 2016 Apr; 18(4):557-64. PubMed ID: 26449250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
    Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
    Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
    West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
    Monestime S; Lazaridis D
    Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT.
    Tap WD; Singh AS; Anthony SP; Sterba M; Zhang C; Healey JH; Chmielowski B; Cohn AL; Shapiro GI; Keedy VL; Wainberg ZA; Puzanov I; Cote GM; Wagner AJ; Braiteh F; Sherman E; Hsu HH; Peterfy C; Gelhorn HL; Ye X; Severson P; West BL; Lin PS; Tong-Starksen S
    Clin Cancer Res; 2022 Jan; 28(2):298-307. PubMed ID: 34716196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
    Baldi GG; Gronchi A; Stacchiotti S
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
    Alsayadi YMMA; Chawla PA
    Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors.
    Lee JH; Chen TW; Hsu CH; Yen YH; Yang JC; Cheng AL; Sasaki SI; Chiu LL; Sugihara M; Ishizuka T; Oguma T; Tajima N; Lin CC
    Invest New Drugs; 2020 Feb; 38(1):99-110. PubMed ID: 30825104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
    Palmerini E; Longhi A; Donati DM; Staals EL
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CSF1 expression in xanthogranulomatous epithelial tumor/keratin-positive giant cell-rich tumor.
    Dehner CA; Lo YC; Chopra S; Demicco EG; He K; Hirbe AC; Folpe AL; Chrisinger JSA
    Hum Pathol; 2024 Jan; 143():1-4. PubMed ID: 37993023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAscope CSF1 chromogenic in situ hybridization: a potentially useful tool in the differential diagnosis of tenosynovial giant cell tumors.
    Thangaiah JJ; Koepplin JW; Folpe AL
    Hum Pathol; 2021 Sep; 115():1-9. PubMed ID: 34058245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
    van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
    J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.